These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8915526)

  • 1. Influence of Uro-Vaxom on sIgA level in urine in children with recurrent urinary tract infections.
    Czerwionka-Szaflarska M; Pawłowska M
    Arch Immunol Ther Exp (Warsz); 1996; 44(2-3):195-7. PubMed ID: 8915526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of the effectiveness of Uro-Vaxom in recurrent urinary tract infections in children].
    Czerwionka-Szaflarska M; Pawłowska M
    Pediatr Pol; 1996 Jul; 71(7):599-604. PubMed ID: 8803463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical assessment of Uro-Vaxom in the treatment and prophylaxis of recurrent urinary tract infection in children: preliminary results].
    Goszczyk A; Bochniewska V; Jung A
    Pol Merkur Lekarski; 2000 Apr; 8(46):242-3. PubMed ID: 10897630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of Uro-Vaxom in treatment of recurrent urinary tract infections in girls].
    Gołabek B; Nowakowska K; Słowik M; Paruszkiewicz G
    Pediatr Pol; 1995 Dec; 70(12):1053-7. PubMed ID: 8649945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Usefulness of Uro-Vaxom in complex treatment of recurrent urinary tract infections in girls].
    Gołabek B; Nowakowska K; Słowik M; Paruszkiewicz G
    Pol Merkur Lekarski; 2002 Apr; 12(70):269-72. PubMed ID: 12089885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uro-Vaxom® versus placebo for the prevention of recurrent symptomatic urinary tract infections in participants with chronic neurogenic bladder dysfunction: a randomised controlled feasibility study.
    Wade D; Cooper J; Derry F; Taylor J
    Trials; 2019 Apr; 20(1):223. PubMed ID: 30992071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal immunity in the urinary tract: changes in sIgA, FSC and total IgA with age and in urinary tract infection.
    James-Ellison MY; Roberts R; Verrier-Jones K; Williams JD; Topley N
    Clin Nephrol; 1997 Aug; 48(2):69-78. PubMed ID: 9285142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells.
    Schmidhammer S; Ramoner R; Höltl L; Bartsch G; Thurnher M; Zelle-Rieser C
    Urology; 2002 Sep; 60(3):521-6. PubMed ID: 12350510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial.
    Magasi P; Pánovics J; Illés A; Nagy M
    Eur Urol; 1994; 26(2):137-40. PubMed ID: 7957468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of vaccination with inactivated uropathogenic bacteria in recurrent urinary tract infections of children.
    Nayir A; Emre S; Sirin A; Bulut A; Alpay H; Tanman F
    Vaccine; 1995 Aug; 13(11):987-90. PubMed ID: 8525693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary sIgA in children with urinary tract infection.
    Fliedner M; Mehls O; Rauterberg EW; Ritz E
    J Pediatr; 1986 Sep; 109(3):416-21. PubMed ID: 3746529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary IgA, secretory IgA and secretory component in women with recurrent urinary tract infections.
    Floege J; Böddeker M; Stolte H; Koch KM
    Nephron; 1990; 56(1):50-5. PubMed ID: 2234249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German Urinary Tract Infection Study Group.
    Tammen H
    Br J Urol; 1990 Jan; 65(1):6-9. PubMed ID: 2178724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of uro-vaxom in recurrent infectious-inflammatory diseases of the urogenital system].
    Kul'chavenia EV; Breusov AA
    Urologiia; 2011; (4):7-11. PubMed ID: 22066233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Importance of individual approach to the immunoprophylaxis of recurrent urogenital infection].
    Kul'chavenia EV; Breusov AA
    Urologiia; 2013; (6):24-6. PubMed ID: 24649759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies.
    Bauer HW; Rahlfs VW; Lauener PA; Blessmann GS
    Int J Antimicrob Agents; 2002 Jun; 19(6):451-6. PubMed ID: 12135831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretory immunoglobulin A and inhibitory activity of bacterial adherence to epithelial cells in urine from patients with urinary tract infections.
    Trinchieri A; Braceschi L; Tiranti D; Dell'Acqua S; Mandressi A; Pisani E
    Urol Res; 1990; 18(5):305-8. PubMed ID: 2124012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Uro-Vaxom--expert in own defence].
    Akush Ginekol (Sofiia); 2008; 47 Suppl 1():28-9. PubMed ID: 18935855
    [No Abstract]   [Full Text] [Related]  

  • 19. Does low urinary sIgA predispose to urinary tract infection?
    Riedasch G; Heck P; Rauterberg E; Ritz E
    Kidney Int; 1983 May; 23(5):759-63. PubMed ID: 6683769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretory IgA in recurrent urinary tract infections in childhood.
    Lancet; 1988 Aug; 2(8608):433-4. PubMed ID: 2900360
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.